Billionaire Phillipe Laffont Dumps Coatue’s Super Micro Computer Stake - Snaps Up Surgical Robotics Pioneer That Soared 19,390% Since IPO

Wall Street's latest pivot play just dropped—and it's surgical.

Billionaire Phillipe Laffont's Coatue Management just executed a massive portfolio shift, dumping its entire Super Micro Computer position while loading up on a surgical robotics disruptor that's posted a mind-bending 19,390% gain since its public debut.

The Strategic Unwind

Laffont isn't just rebalancing—he's completely rewiring his tech exposure. The move signals a massive vote of confidence in medical technology's convergence with AI, betting that precision robotics will outperform traditional compute plays in the coming cycle.

Timing the Tides

While the Street chases last quarter's winners, Coatue's surgical exit from Super Micro and precision entry into robotics shows institutional money is already positioning for the next paradigm shift. Because nothing says 'conviction' like dumping a position to chase a 19,390% runner—what could possibly go wrong?

Image source: Getty Images.

Coatue bought into Supermicro at a controversial moment, but it seems Laffont had a change of heart. At the end of June, there were zero shares of the custom server builder in its portfolio.

While Coatue was disposing of Supermicro with its left hand, it was buying up shares of(ISRG -1.34%) with its right. The hedge fund snapped up 39,512 shares of the robot-assisted surgery pioneer in the second quarter.

Intuitive Surgical stock has tumbled this year, but Laffont has reasons to expect a rebound. Here's a look at what they are to see whether this stock could be a good fit for your portfolio.

An unbeatable advantage

When the market closed on Sept. 12, 2025, shares of Intuitive Surgical were up 19,390% since its initial public offering (IPO) 25 years ago. A few years before its IPO, the Food and Drug Administration made the company's da Vinci robotic surgical system the first one with clearance to assist with minimally invasive abdominal surgeries.

,, andmarket surgical robots, but they entered the market after Intuitive Surgical. The pioneer is still the largest member of its industry. At the end of 2024, there were 11,040 Intuitive Surgical systems installed in hospitals worldwide.

Intuitive's massive installed base of machines isn't sitting idle either. Surgical teams trained to use da Vinci systems performed 2.7 million procedures last year. Plus, Ion, its more recently launched lung tumor biopsy machine, performed 95,000 procedures last year.

To date, competing systems generally address procedures that don't already employ da Vinci systems, such as knee replacements and spinal surgeries. Hospital systems can spend more than $1 million installing a da Vinci system and then an even larger sum supporting and training the professionals who will use it. That's a huge advantage over newer surgical systems that competitors probably won't be able to overcome.

Placing systems and training surgeons to use them generates revenue for Intuitive, but these aren't the main sources. Around 84% of total revenue last year came from recurring sources such as instruments and accessories that must be replaced before each procedure.

Why Intuitive Surgical stock is down

Intuitive Surgical has been a terrific stock for its long-term shareholders, but it's been a stinker this year. It's down about 26% from a peak it set in February.

Fear that tariffs will pressure profit margins has been a weight on Intuitive Surgical's stock price. When reporting second-quarter results in July, management reduced its adjusted gross profit margin expectation to a range between 66% and 67%. That WOULD be a minor decline from the 69.1% gross margin reported last year, but this temporary setback is hardly a reason to avoid the stock.

Earlier this year, Medtronic submitted an application to the Food and Drug Administration to perform urology procedures with its Hugo RAS system. Roughly one-fifth of all procedures performed with da Vinci machines last year were in the urology category.

Investors concerned that the Hugo system will pull market share from da Vinci should know that its launch overseas hasn't been very successful. It's been authorized for sale in the European Union since 2021, but Medtronic still doesn't tell investors how much revenue Hugo's generating in its quarterly reports.

Time to buy?

In the U.S., hospitals considering a new surgical system for urologic surgeries could have a new option from Medtronic by the end of the year. Luckily for Intuitive Surgical, the da Vinci 5 system, which launched in March 2024, already makes Medtronic's Hugo system seem outdated.

Despite tariff pressure, investors can expect significant growth from Intuitive Surgical. Management is forecasting overall procedure growth of 15.5% to 17.0% this year. High switching costs for hospitals could lead to procedure growth that continues rising for another decade or two.

With a stock price that's been trading at 55.3 times forward earnings expectations, investors are already expecting profit growth at a double-digit percentage for years to come. Intuitive Surgical stock could fall hard if Medtronic or another competitor begins pressuring sales growth in the years ahead.

Given Hugo's performance in the E.U., threats from well-heeled competitors appear toothless. Adding some shares to a diverse portfolio now could be the right MOVE for investors with a high risk tolerance.